mTOR pathway inhibition and time-dependent AKT rebound in breast cancer cells
Cell-based study · MCF-7, BT-474 and MDA-MB-468 human breast cancer cells; AKT activity time course in BT-474 cells. [1]
AZD8055 reduced phosphorylation of mTORC1 substrates and AKT Ser473. In BT-474 and MDA-MB-468 cells, AKT Thr308 and downstream substrate phosphorylation recovered despite persistent Ser473 suppression. This limits the use of Ser473 alone as a measure of sustained AKT inhibition.
| Endpoint | Reported result | Reference |
|---|---|---|
| p70S6K Thr389, S6 Ser240/244, 4E-BP1 and AKT Ser473 phosphorylation | Qualitative immunoblot response Suppression of mTORC1/2 signaling; 4E-BP1 suppression required more drug/time than p70S6K suppression. | [1] |
| AKT Thr308 and AKT-substrate phosphorylation | Time-dependent response Rebound began at 4 h; phosphorylation reached pretreatment levels at 8–16 h while AKT Ser473 remained inhibited. | [1] |
| AKT kinase activity in immunoprecipitates from treated BT-474 cells | Activity relative to baseline 15% of baseline at 8 h; 60% at 24 h | [1] |
Literature-Reported Treatment Conditions
- Treatment concentration
- AZD8055: 0, 10, 20, 100, 200 and 500 nM for concentration response; 500 nM for time courses.
- Exposure duration
- 4 h concentration response; time courses through 24 h.
- Method
- Cell exposure followed by immunoblotting or AKT activity measurement in cell-derived immunoprecipitates.
- Co-treatment
- No combination adopted. Rapamycin was a separate comparator in Figure 1A.
- Reported limits
- AZD8055-specific vehicle, replicate count and complete AKT assay supplement were not established from the inspected main text. Concentrations are experimental conditions, not recommendations.
Methods and source locations
Compound reported in the paper: AZD8055; Compound label in the paper: AZD8055
Results apply to the reported research material and model; no batch equivalence or product validation is asserted.
Figures 1A–B and 2A–C; corresponding Results; Cell culture and reagents; Immunoblot analysis; In vitro AKT kinase assay
p70S6K Thr389, S6 Ser240/244, 4E-BP1 and AKT Ser473 phosphorylation: Immunoblotting with actin loading controls and untreated lanes; comparison with rapamycin. — Figure 1A–B and caption; first Results subsection; Immunoblot analysis
AKT Thr308 and AKT-substrate phosphorylation: Immunoblot time course, with untreated baseline and actin controls; no band intensities estimated. — Figure 2A–B, panel 1; Results paragraphs on transient AKT inhibition
AKT kinase activity in immunoprecipitates from treated BT-474 cells: Cell Signaling AKT kinase assay; densitometry. Values stated in Results; Figure 2C error bars are standard error; n not specified in the inspected text/caption. — Figure 2C and caption; Results paragraph beginning To confirm; In vitro AKT kinase assay